Stoke Therapeutics, Inc.
STOK
$31.27
-$0.04-0.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 27.59M | 32.08M | 184.42M | 205.63M | 199.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.59M | 32.08M | 184.42M | 205.63M | 199.89M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 27.59M | 32.08M | 184.42M | 205.63M | 199.89M |
| SG&A Expenses | 82.40M | 72.41M | 67.09M | 58.79M | 55.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 250.97M | 217.33M | 205.01M | 178.44M | 159.61M |
| Operating Income | -223.38M | -185.25M | -20.59M | 27.20M | 40.28M |
| Income Before Tax | -209.18M | -171.05M | -6.89M | 40.57M | 53.76M |
| Income Tax Expenses | -1.28M | -1.28M | 0.00 | 0.00 | 1.28M |
| Earnings from Continuing Operations | -207.90 | -169.77 | -6.89 | 40.57 | 52.48 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -207.90M | -169.77M | -6.89M | 40.57M | 52.48M |
| EBIT | -223.38M | -185.25M | -20.59M | 27.20M | 40.28M |
| EBITDA | -221.63M | -183.52M | -18.82M | 29.09M | 42.27M |
| EPS Basic | -3.31 | -2.78 | -0.04 | 0.71 | 0.90 |
| Normalized Basic EPS | -2.09 | -1.75 | -0.02 | 0.44 | 0.57 |
| EPS Diluted | -3.32 | -2.79 | -0.10 | 0.66 | 0.84 |
| Normalized Diluted EPS | -2.09 | -1.75 | -0.06 | 0.41 | 0.54 |
| Average Basic Shares Outstanding | 249.73M | 242.07M | 236.87M | 231.86M | 229.59M |
| Average Diluted Shares Outstanding | 249.73M | 242.07M | 238.40M | 233.39M | 231.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |